MYNZ
Mainz Biomed B.V. [MYNZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MYNZ Stock Summary
Top 10 Correlated ETFs
MYNZ
Top 10 Correlated Stocks
MYNZ
In the News
MYNZ Financial details
Company Rating
-
Market Cap
16.25M
Income
-29.37M
Revenue
874K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
58
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.6
Forward P/E
-
PEG
-0.33
P/S
18.41
P/B
5.09
P/C
-
P/FCF
-0.68
Quick Ratio
0.87
Current Ratio
0.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.97
EPS next Y
-
EPS next Q
-
EPS this Y
11.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-27.02%
EPS Q/Q
-29.09%
-
-
-
-
SMA20
35.23%
SMA50
-18.34%
SMA100
-30.85%
Inst Own
-
Inst Trans
-
ROA
-164%
ROE
-363%
ROC
-4.29%
Gross Margin
47%
Oper. Margin
-3262%
Profit Margin
-3361%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.85-6.07
52W High
-
52W Low
-
RSI
47.16
Rel Volume
2.5
Avg Volume
86.22K
Volume
215.23K
Perf Week
-27.25%
Perf Month
22.91%
Perf Quarter
-59.43%
Perf Half Y
-59.63%
-
-
-
-
Beta
0.169
-
-
Volatility
0.71%, 1.12%
Prev Close
2.5%
Price
5.74
Change
12.77%
Company Profile
- Volume Average 86.22K
- Market Capitalization 16.25M
- Employee 58
- CEO Mr. William J. Caragol
- Headquarters Mainz,DE
- IPO Date 2021-11-05
-
Website
https://mainzbiomed.com 
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
